Cubist Pharmaceuticals Appoints Robert J. Perez Head of Sales & Marketing; Cubist Hires 70 of 75 Sales Representatives.Business Editors/Health/Medical Writers LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 25, 2003 Cubist Pharmaceuticals, Inc. (Nasdaq: CBST CBST Center for Biophotonics Science and Technology CBST Congregation Beth Simcha Torah (NYC) CBST Complete Binary Search Tree ) today announced that it has appointed Robert J. Perez to the newly created position of Senior Vice President, Sales & Marketing. Cubist is currently awaiting action on the New Drug Application (NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any ) for its investigational antibiotic Cidecin(R) (daptomycin for injection) by the U.S. Food & Drug Administration. Cubist also announced today that it has now hired 70 of the 75 sales representatives planned for the launch of CIDECIN in the U.S., should it receive marketing clearance. In this new role, Mr. Perez will lead Cubist's efforts to commercialize its products. He comes to Cubist from Biogen, Inc., where he had served as Vice President of Biogen's CNS See Continuous net settlement. CNS See continuous net settlement (CNS). Business Unit since 2001 and was responsible for leading the U.S. neurology franchise, including Biogen's flagship product Avonex(R), along with customer support, medical affairs, reimbursement and training. From 1995 to 2001, he served as a Regional Director, Director of Sales, and AVONEX Commercial Executive at Biogen. From 1987 to 1995, Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals, ultimately serving as Regional Business Manager, responsible for strategic planning and profitability of a key business unit and managing both national and regional sales managers. Mr. Perez received a BS from California State University, Los Angeles California State University, Los Angeles (also known as Cal State L.A., CSULA, or "'CSLA"') is a public university, part of the California State University system. and an MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration from The Anderson School at UCLA UCLA University of California at Los Angeles UCLA University Center for Learning Assistance (Illinois State University) UCLA University of Carrollton, TX and Lower Addison, TX . Michael W. Bonney, Cubist's President & Chief Executive Officer said, "We are very pleased to have Rob joining the senior management team at Cubist at this exciting time in the company's history. We believe his operational, managerial and strategic planning experience will prove invaluable as we prepare for the anticipated November launch of CIDECIN, pending approval. With Rob's hiring, along with the vast majority of our sales representatives, we are now looking forward to transitioning from our recruiting and planning phase to the implementation phase of our commercialization efforts." About Cubist Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of antiinfective drugs. Cubist has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) for Cidecin(R) (daptomycin for injection) for the treatment of complicated skin and skin structure infections. The NDA for CIDECIN is currently being reviewed by the FDA under priority review status. Cubist's pipeline includes CAB-175, a next-generation parenteral parenteral /pa·ren·ter·al/ (pah-ren´ter-al) not through the alimentary canal, but rather by injection through some other route, as subcutaneous, intramuscular, etc. par·en·ter·al adj. 1. cephalosporin cephalosporin (sĕf'əlōspôr`ĭn), any of a group of more than 20 antibiotics derived from species of fungi of the genus Cephalosporium and closely related chemically to penicillin. Cephalosporins, e.g. antibiotic in Phase 1 trials, and an oral version of ceftriaxone ceftriaxone /cef·tri·ax·one/ (cef?tri-ak´son) a semisynthetic, ß–resistant, third-generation cephalosporin effective against a wide range of gram-positive and gram-negative bacteria, used as the sodium salt. (OCTX), a broad-spectrum cephalosporin antibiotic in pre-clinical development. Cubist is headquartered in Lexington, MA. Cubist Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by the Company. These factors include, but are not limited to: (i) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies and commercialization; (ii) the Company's ability to obtain required governmental approvals; (iii) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; (iv) the Company's ability to develop and commercialize its products before its competitors; and (v) the Company's ability to finance its operations. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in the Company's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in the Company's recent SEC filings. Cidecin is a registered trademark of Cubist Pharmaceuticals, Inc. Additional information can be found at the Company's web site at www.cubist.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion